Driehaus Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Driehaus Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-139,007	Closed	-$1.85M	–	557
2013 Q3	$1.85M	Sell	139,007 -3,096	-2%	-$48.9K	0.07%	290
2013 Q2	$1.87M	Buy	+142,103	New	+$1.92M	0.08%	276

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AWMDMG

Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Driehaus Capital Management's ECYT Position: Q4 2013 in Review

Driehaus Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2013, closing a stake of 139,007 shares — an estimated $1.85M sold.

Driehaus Capital Management first reported a position in ECYT in Q2 2013 and held it in 2 quarters. The position peaked at $1.87M in Q2 2013. 90 funds tracked by Wall St. Rank hold ECYT as of Q4 2013.

Driehaus Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
Driehaus Capital Management sold 139,007 Endocyte, Inc. Common Stock shares in Q4 2013, an estimated $1.85M.
Driehaus Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
Driehaus Capital Management's Endocyte, Inc. Common Stock position peaked at $1.87M in Q2 2013.
90 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2013.

Based on Driehaus Capital Management's 13F filing for Q4 2013, filed 13 Feb 2014.